GLP-2 TZ
For laboratory research use only — not for human or animal consumption.
Research-grade tirzepatide (GLP-2 TZ), a 39-amino acid dual GIP/GLP-1 receptor agonist peptide, ≥99% HPLC purity with third-party batch-level Certificate of Analysis. For laboratory research use only.
Description
GLP-2 TZ
GLP-2 TZ is a long-acting dual agonist peptide targeting GLP-1 and GIP receptors. Preclinical research examines its incretin-receptor pharmacology, glucose homeostasis, and energy-balance endpoints in rodent and cell-based models.
Key Research Areas
- • Studied for dual agonism at GLP-1R and GIPR for synergistic incretin-receptor signaling in receptor-expressing cell lines.
- • Investigated for body-weight and energy-balance endpoints in diet-induced obese rodent models.
- • Explored for enhancements in glycemic control, insulin secretion, and lipid metabolism in obesity and diabetes models.
Product Specifications
| Product | GLP-2 TZ |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Molar Mass | 4813.45 g/mol |
| Sequence | Modified lipidated 39-amino acid dual agonist peptide |
| Synonyms | GLP-2 TZ; Tirz; LY3298176; dual GIP/GLP-1 agonist |
| Purity | ≥99% (HPLC) |
| Form | Lyophilized powder |
| Storage | −20°C (−4°F) long-term; 2–8°C (36–46°F) reconstituted |
| Solubility | Bacteriostatic water for laboratory use |
Mechanism of Action
Tirzepatide is a 39-amino acid synthetic peptide engineered from the GIP sequence with a C20 fatty di-acid moiety that binds albumin and extends its half-life. In receptor-expressing cell lines it acts as an agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, with reported bias toward cAMP signaling over β-arrestin recruitment at GLP-1R. In diet-induced obese rodent models this dual agonism has been associated with improved glucose tolerance, insulin secretion, and energy-balance endpoints beyond single-receptor GLP-1 agonism. Observations summarized here derive from in vitro assays and animal models; the material sold on this page has not been evaluated in controlled human trials.
Research Literature
- • Coskun et al. (2018) — discovery pharmacology of LY3298176 (tirzepatide) as a dual GIP/GLP-1 receptor agonist, including in vitro receptor activity and rodent studies. PMID: 30473097.
- • Liu et al. (2024) — review of mechanisms of action of GLP-1 and dual GIP/GLP-1 receptor agonists. PMID: 39114288.
- • Additional peer-reviewed literature is indexed on PubMed under the compound name.
Reconstitution & Storage
Lyophilized tirzepatide is stable at −20°C or colder in its sealed vial; −80°C is preferable for long-term archival. Reconstitute in bacteriostatic water (0.9% benzyl alcohol) to a laboratory working concentration of 0.5–2 mg/mL for in vitro use. Once reconstituted, refrigerate at 2–8°C and use within approximately 30 days. Aliquot into single-use vials at reconstitution to avoid repeated freeze-thaw cycles of the working solution. Every batch ships with a third-party Certificate of Analysis; request the analytical file for your batch at /coa.
Research Use Only
For research use only. Not intended for human or veterinary consumption, therapeutic use, dietary supplementation, cosmetic use, or clinical application. Not FDA-approved. Purchasers confirm the material will be used solely for in vitro laboratory research and not administered to humans or animals.